Basket 02 — Iron Complex Finished Dosages

Iron Complex
Finished Dosage Basket

Selected iron complex finished dosage and mineral salt basket for haematology, anaemia and mineral supplementation — for website approval.

The Clinical Case

"Simple ferrous salts were first-line for half a century — but 40–60% of patients stop before reaching therapeutic iron targets."

Iron deficiency anaemia affects 1.2 billion people worldwide — the most prevalent nutritional deficiency on the planet. In India, NFHS-5 data shows 57% of women aged 15–49 and 67% of children under five are anaemic. It remains the leading cause of preventable maternal mortality. The scale is not a distant public health statistic; it is the clinical reality facing every haematologist, obstetrician, and general physician in this country daily.

The clinical management of IDA has changed radically over two decades. Simple ferrous salts — the default for half a century — carry GI intolerance that causes 40–60% of patients to discontinue before reaching therapeutic targets. Polysaccharide-iron complexes represent the next chapter: a protected matrix that delivers elemental iron past the stomach without the oxidative irritation of free ferrous ions. Superior tolerability translates directly to superior adherence — and adherence is the primary determinant of therapeutic outcome in chronic iron supplementation.

The inflection point in IV iron came with high-stability complexes — Ferric Carboxymaltose and Iron Isomaltoside. These allow a clinician to replace the entire iron deficit (1,000–1,500 mg) in a single 15-minute infusion. For a post-bariatric patient, a Crohn's patient, or a chronic kidney disease patient on ESA therapy, this is not a convenience — it is the difference between therapeutic success and failure. The system cost economics are compelling: one TDI visit versus five multi-session iron sucrose visits at the same hospital.

API Portfolio

Market Intelligence